Baseline and post-treatment fibrosis-4 scores to predict hepatocellular carcinoma after direct-acting antiviral therapy
{{output}}
Introduction: Patients with chronic hepatitis C remain at risk of hepatocellular carcinoma (HCC) even after attaining sustained virological response at 12 weeks (SVR12). The optimal strategy to stratify HCC risk, particularly in ... ...
